ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 460,800 shares, a decrease of 20.6% from the March 31st total of 580,600 shares. Currently, 6.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,410,000 shares, the short-interest ratio is presently 0.2 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $120.00 price objective on shares of ZyVersa Therapeutics in a report on Tuesday, March 26th.

ZyVersa Therapeutics Trading Up 15.6 %

ZVSA opened at $5.77 on Tuesday. The stock has a 50-day moving average price of $7.64 and a 200-day moving average price of $14.20. ZyVersa Therapeutics has a 12-month low of $4.44 and a 12-month high of $220.85.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.